Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 2Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 7Oxaliplatin 5Cisplatin 4tremelimumab 3durvalumab 3Radiotherapy 3Paclitaxel 3Leucovorin 3Surgical Procedures, Operative 2Radiation 2Docetaxel 2Cetuximab 2Carboplatin 2Capecitabine 2zanidatamab 1trastuzumab deruxtecan 1rucaparib 1oblimersen 1monalizumab 1cabozantinib 1benzamide 1Trastuzumab 1Taxes 1Ramucirumab 1Nivolumab 1Neoadjuvant Therapy 1Microarray Analysis 1Metabolic Networks and Pathways 1LY2940680 1Immunohistochemistry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Adenocarcinoma Of Esophagus × AMG 337 × Clear all
NCT02344810 2023-05-25

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Eastern Cooperative Oncology Group

Phase 1/2 Withdrawn
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gastrointestinal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡